权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Drug Dependence Clinical Research Program

药物依赖性临床研究计划

基本信息

批准号：
10627879
负责人：
Peyton Jacob
金额：
$ 78.29万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
起止时间：
1999-09-01 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10627879
关键词：
Analytical Chemistry Applications Grants Biological Markers Cannabis Cardiology Cessation of life Chemistry Clinic Clinical Research Country Data Analyses Dentistry Development Discipline Drug Addiction Drug Kinetics Drug abuse Drug usage Exposure to Faculty Funding Future Goals Grant Harm Reduction Health Human Individual Infrastructure Institution Institutional Review Boards Internal Medicine Laboratories Learning Manuscripts Measures Mentors Methods Modality National Institute of Drug Abuse Occupational Medicine Pediatrics Persons Pharmaceutical Preparations Pharmacology Study Pharmacotherapy Pilot Projects Poison Postdoctoral Fellow Preparation Prevention Prevention program Psychiatry Psychology Psychotropic Drugs Public Health Public Policy Pulmonology Request for Applications Research Research Design Research Personnel Research Priority Research Project Grants Research Support Research Training Resources Risk Services Smoking Substance abuse problem Tobacco Tobacco Dependence Toxicology United States National Institutes of Health addiction analytical method career career development cost cost effective design drug of abuse effective therapy environmental tobacco smoke exposure experience exposed human population health assessment human subject improved instrument member method development premature programs public health research response skills synergism thirdhand smoke tobacco products treatment program treatment strategy

项目摘要

ABSTRACT – OVERALL COMPONENT This Core Support Center Grant (P30) application requests continued support for an analytical chemistry laboratory and administrative shared core infrastructure, and support for a pilot project core. The participating, currently funded, constituent projects continue research programs with human laboratory and treatment clinic studies of the clinical pharmacology of abused drugs, pharmacotherapies and other treatment strategies to treat drug abuse and addictions, and studies of the underlying causes and health consequences of drug addiction with the goal of improving therapies, reducing harm, and guiding public policy. Disciplines represented by the participating projects and investigators include psychiatry, psychology, internal medicine, cardiology, occupational medicine, pulmonary medicine, pediatrics, toxicology, environmental public health, dentistry, and chemistry. Currently, most of the supported projects involve the problems associated with tobacco addiction, but some are studies of cannabis and these are increasing with grant proposals submitted or in preparation. We are prepared to support studies of other abused drugs as well, with validated methods used in past studies, as well as the capability to develop new methods. Projects supported by the Pilot Project Core will likely involve other drugs of abuse, facilitated by encouraging scholars in UCSF's Learning for Early Careers in Addiction & Diversity (LEAD) Program whose studies involve a variety of abused substances, to apply for pilot project funding. Our aims are: (1) To provide a state-of-the-art, well equipped and staffed, analytical chemistry laboratory resource for the participating projects of drug abuse researchers at UCSF and at other institutions. (2) A Pilot Project Core with the overarching goal of building a pipeline of investigators with the skills and experience to conduct high quality, cutting edge, and/or rapid response research in substance abuse and prevention. (3) To provide administrative support for manuscript preparation, IRB and related regulatory documents, grants management, and other research administrative services of value participating projects. (4) To provide statistical consulting services regarding study design and data analysis strategies, particularly optimal pharmacokinetic analysis to participating projects. The overall objective is to provide sophisticated analytical laboratory resources with stability of support together with adequate administrative support responsive to the needs of individual funded constituent scientific projects as those projects change and evolve. This facility is a cost-effective shared laboratory resource that enhances and extends research possibilities of investigators currently funded by NIH or other federal or nonfederal agencies to further our understanding of human psychoactive drug use, abuse and addiction, its health consequences and its treatment management.

抽象-整体组件此核心支持中心助学金(P30)申请继续支持分析化学实验室和行政部门共享核心基础设施，并支持试点项目核心。参赛者，目前得到资助的组成项目继续与人体实验室和治疗诊所进行研究计划。滥用药物的临床药理、药物治疗和其他治疗策略的研究治疗药物滥用和上瘾，研究毒品的根本原因和对健康的影响以改进治疗、减少危害和指导公共政策为目标的上瘾。学科参与项目和调查人员的代表包括精神病学、心理学、内科、心脏病学、职业医学、肺部医学、儿科学、毒理学、环境公共卫生、牙科和化学。目前，大多数受支持的项目都涉及与以下方面相关的问题烟草成瘾，但有些是关于大麻的研究，随着拨款提案的提交，这些研究正在增加或者是在准备中。我们也准备支持对其他滥用药物的研究，并采用经过验证的方法在过去的研究中使用，以及开发新方法的能力。试点项目支持的项目 CORE可能会涉及其他药物滥用，通过鼓励加州大学旧金山分校的学者早期学习来促进研究涉及各种滥用物质的成瘾与多样性(LEAD)计划的职业，申请试点项目资金。我们的目标是：(1)提供一流、设备齐全、人员齐全的加州大学旧金山分校药物滥用研究人员参与项目的分析化学实验室资源在其他机构。(2)以建立调查人员渠道为总体目标的试点项目核心具备进行高质量、尖端和/或快速响应研究的技能和经验药物滥用和预防。(3)为稿件准备、内部评审委员会和相关法规文件、拨款管理和其他有价值的研究行政服务参与项目。(4)提供研究设计和数据分析方面的统计咨询服务战略，特别是对参与项目的最佳药代动力学分析。总体目标是提供成熟的分析实验室资源和稳定的支持，以及足够的响应个人资助的组成科学项目的需求的行政支持，如项目会不断变化和发展。该设施是一种经济高效的共享实验室资源，可增强和扩展目前由NIH或其他联邦或非联邦机构资助的调查人员的研究可能性为了加深我们对人类精神活性药物的使用、滥用和成瘾及其对健康的影响的理解及其治疗管理。

项目成果

期刊论文数量（200）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Sources and Biomarkers of Secondhand Tobacco Smoke Exposure in Urban Adolescents.

DOI：
10.1016/j.acap.2019.12.006
发表时间：
2020-05
期刊：
Academic pediatrics
影响因子：
3.1
作者：
Nardone N;Jain S;Addo N;St Helen G;Jacob P 3rd;Benowitz NL
通讯作者：
Benowitz NL

Urinary NNAL in hookah smokers and non-smokers after attending a hookah social event in a hookah lounge or a private home.

DOI：
10.1016/j.yrtph.2017.07.009
发表时间：
2017-10
期刊：
Regulatory toxicology and pharmacology : RTP
影响因子：
0
作者：
Kassem NOF;Kassem NO;Liles S;Jackson SR;Chatfield DA;Jacob P 3rd;Benowitz NL;Hovell MF
通讯作者：
Hovell MF

The clinical pharmacology of intranasal l-methamphetamine.

DOI：
10.1186/1472-6904-8-4
发表时间：
2008-07-21
期刊：
BMC clinical pharmacology
影响因子：
0
作者：
Mendelson, John E;McGlothlin, Dana;Harris, Debra S;Foster, Elyse;Everhart, Tom;Jacob, Peyton 3rd;Jones, Reese T
通讯作者：
Jones, Reese T

Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity.